Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00716911 Completed - Lymphoma Clinical Trials

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Start date: January 2000
Phase: N/A
Study type: Interventional

RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant. PURPOSE: This clinical trial is studying tests that measure changes in the blood in patients at high risk of cytomegalovirus infection after undergoing donor bone marrow transplant or peripheral stem cell transplant.

NCT ID: NCT00716417 Completed - Neoplasms Clinical Trials

Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours

Start date: July 2008
Phase: Phase 1
Study type: Interventional

Study to determine the maximum tolerated dose of BIBW 2992 when combined with backbone chemotherapies consisting in cisplatin plus paclitaxel or cisplatin plus 5 FU. The overall safety, the pharmacokinetics and the anti-tumour efficacy will also be assessed.

NCT ID: NCT00715403 Completed - Neoplasms Clinical Trials

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Start date: October 2004
Phase: Phase 1
Study type: Interventional

The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in terms of incidence and intensity of Adverse Events and changes in safety laboratory parameters. Secondary objectives are the collection of further safety data (vital signs), efficacy data and the determination of pharmacokinetic characteristics during long-term therapy with BIBF 1120.

NCT ID: NCT00714701 Completed - Clinical trials for Familial Pancreatic Neoplasia

Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)

CAPS4
Start date: June 2008
Phase:
Study type: Observational

CAPS4 is a study at Johns Hopkins Hospital to study the diagnosis and long-term outcomes of screening patients with an increased inherited risk for pancreatic cancer.

NCT ID: NCT00713427 Completed - Clinical trials for Biliary Strictures Caused by Malignant Neoplasms

Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

Start date: July 2007
Phase: N/A
Study type: Interventional

This is a a prospective study of the WallFlex™ Biliary Partially-covered Stent designed to collect data to support regulatory clearance by the FDA in the United States and to determine the functionality of the WallFlex™ Biliary Partially Covered Stent as a Palliative treatment for malignant bile duct obstruction.

NCT ID: NCT00712218 Completed - Ovarian Cancer Clinical Trials

Lymphadenectomy In Ovarian Neoplasms

LION
Start date: December 2008
Phase: N/A
Study type: Interventional

To assess the efficacy of systematic pelvic and para-aortic lymphadenectomy in patients with advanced ovarian cancer and intra-abdominal complete debulking. Secondary: progression-free survival, complications and quality of life; Exploratory: Role of number of resected lymph nodes for primary and secondary objectives

NCT ID: NCT00710736 Completed - Advanced Cancer Clinical Trials

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine. Patients will receive increasing doses of study drug in combination with capecitabine in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 30 patients from the US and Canada will be enrolled in this study.

NCT ID: NCT00709176 Completed - Advanced Cancer Clinical Trials

Outcomes of Triaged Family Care in Advanced Cancer

FOCUS-Triage
Start date: June 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the quality of life of patients with advanced cancer and their family caregivers and to evaluate two doses of a family-based program of care versus control.

NCT ID: NCT00708591 Completed - Advanced Cancer Clinical Trials

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

Start date: October 2004
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose, observed toxicities, and dose limiting toxicities, and antitumor response of rapamycin plus ketoconazole in patients with advanced cancers.

NCT ID: NCT00707135 Completed - Advanced Cancer Clinical Trials

Rapamycin in Advanced Cancers

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.